The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 09, 2024
Filed:
Nov. 08, 2021
Celgene Corporation, Summit, NJ (US);
Matthew D. Alexander, San Diego, CA (US);
Gerald D. Artman, Asbury, NJ (US);
Gordon L. Bray, San Francisco, CA (US);
James Carmichael, Nottingham, GB;
Soraya Carrancio, San Diego, CA (US);
Brian E. Cathers, San Diego, CA (US);
Matthew D. Correa, San Diego, CA (US);
Joshua Hansen, La Jolla, CA (US);
Courtney G. Havens, San Diego, CA (US);
Timothy S. Kercher, Longmont, CO (US);
Antonia Lopez-Girona, San Diego, CA (US);
Xiaoling Lu, Whippany, NJ (US);
Hon-Wah Man, Princeton, NJ (US);
Mark A. Nagy, Encinitas, CA (US);
Rama K. Narla, San Diego, CA (US);
Joseph R. Piccotti, Encinitas, CA (US);
Daniel W. Pierce, Belmont, CA (US);
Paula A. Tavares-Greco, Parsippany, NJ (US);
Brandon W. Whitefield, San Diego, CA (US);
Lilly L. Wong, Solana Beach, CA (US);
Nanfei Zou, Fanwood, NJ (US);
Celgene Corporation, Summit, NJ (US);
Abstract
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.